{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:40:36Z","timestamp":1790602836815,"version":"4.1.0"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100001117","name":"amfAR","doi-asserted-by":"publisher","award":["110408-RGRL"],"award-info":[{"award-number":["110408-RGRL"]}],"id":[{"id":"10.13039\/100001117","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BEAT-HIV Delaney Collaboratory","award":["UM1 AI164570"],"award-info":[{"award-number":["UM1 AI164570"]}]},{"name":"BEAT-HIV Delaney Collaboratory","award":["P30 AI045008"],"award-info":[{"award-number":["P30 AI045008"]}]},{"DOI":"10.13039\/100010633","name":"Philadelphia Foundation","doi-asserted-by":"publisher","award":["UM AI164570"],"award-info":[{"award-number":["UM AI164570"]}],"id":[{"id":"10.13039\/100010633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Natural killer (NK) cells can efficiently mediate antibody-dependent cellular cytotoxicity (ADCC) of antibody coated target cells via the low-affinity Fc-receptor, CD16, but cannot retain antibodies over time. To increase antibody retention and facilitate targeted ADCC, we genetically modified human NK cells with the high-affinity Fc receptor, CD64, so that we could preload them with HIV-specific broadly neutralizing antibodies (BNAbs) and enhance their capacity to target HIV-infected cells via ADCC. Purified NK cells from the peripheral blood of control donors or persons living with HIV were activated with interleukin (IL)-2\/IL-15\/IL-21 cytokines and transduced with a lentivirus encoding CD64. High levels of CD64 surface expression were maintained for multiple weeks on NK cells and CD64-transduced NK cells were phenotypically similar to control NK cells with strong expression of CD56, CD16, NKG2A, NKp46, CD69, HLA-DR, CD38, and CD57. CD64-transduced NK cells exhibited significantly greater capacity to bind HIV-specific BNAbs in short-term antibody binding assay as well as retain the BNAbs over time (1-wk antibody retention assay) compared with control NK cells only expressing CD16. BNAb-preloaded CD64-transduced NK cells showed a significantly enhanced capacity to mediate ADCC against autologous HIV-1\u2013infected CD4+ primary T cells in both a short-term 4\u2009h degranulation assay as well as a 24\u2009h HIV p24 HIV elimination assay when compared with control NK cells. A chimeric CD64 enhanced NK cell strategy (NuKEs [NK Enhancement Strategy]) retaining bound HIV-specific BNAbs represents a novel autologous primary NK cell immunotherapy strategy against HIV through targeted ADCC.<\/jats:p>","DOI":"10.1093\/jimmun\/vkae028","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T15:03:16Z","timestamp":1739804596000},"page":"253-264","source":"Crossref","is-referenced-by-count":10,"title":["Gene-modified NK cells expressing CD64 and preloaded with HIV-specific BNAbs target autologous HIV-1\u2013infected CD4+ T cells by ADCC"],"prefix":"10.1093","volume":"214","author":[{"given":"Costin","family":"Tomescu","sequence":"first","affiliation":[{"name":"HIV Immunopathogenesis Laboratory, BEAT-HIV Delaney Collaboratory, Wistar Institute , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3076-2145","authenticated-orcid":false,"given":"Adiana","family":"Ochoa-Ortiz","sequence":"additional","affiliation":[{"name":"HIV Immunopathogenesis Laboratory, BEAT-HIV Delaney Collaboratory, Wistar Institute , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily D","family":"Lu","sequence":"additional","affiliation":[{"name":"Molecular Screening and Protein Expression Facility, Wistar Institute , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Kong","sequence":"additional","affiliation":[{"name":"Center for Cellular Immunotherapies, BEAT-HIV Delaney Collaboratory, Department of Microbiology, University of Pennsylvania Perelman School of Medicine , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L","family":"Riley","sequence":"additional","affiliation":[{"name":"Center for Cellular Immunotherapies, BEAT-HIV Delaney Collaboratory, Department of Microbiology, University of Pennsylvania Perelman School of Medicine , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5799-6759","authenticated-orcid":false,"given":"Luis J","family":"Montaner","sequence":"additional","affiliation":[{"name":"HIV Immunopathogenesis Laboratory, BEAT-HIV Delaney Collaboratory, Wistar Institute , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"2025030420230820900_vkae028-B1","doi-asserted-by":"crossref","first-page":"663919","DOI":"10.3389\/fimmu.2021.663919","article-title":"Anti-HIV-1 ADCC and HIV-1 env can be partners in reducing latent HIV reservoir","volume":"12","author":"Suryawanshi","year":"2021","journal-title":"Front Immunol"},{"key":"2025030420230820900_vkae028-B2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/infdis\/jiaa165","article-title":"Antibodies for human immunodeficiency virus-1 cure strategies","volume":"223","author":"Rossignol","year":"2021","journal-title":"J Infect Dis"},{"key":"2025030420230820900_vkae028-B3","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.3389\/fimmu.2018.02429","article-title":"Antibodies and antibody derivatives: new partners in HIV eradication strategies","volume":"9","author":"Carrillo","year":"2018","journal-title":"Front Immunol"},{"key":"2025030420230820900_vkae028-B4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3389\/fimmu.2015.00265","article-title":"Can HIV-1-specific ADCC assist the clearance of reactivated latently infected cells?","volume":"6","author":"Lee","year":"2015","journal-title":"Front Immunol"},{"key":"2025030420230820900_vkae028-B5","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/COH.0b013e32835fe6d2","article-title":"Immune control of HIV-1 reservoirs","volume":"8","author":"Autran","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"key":"2025030420230820900_vkae028-B6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/jleuko\/qiac007","article-title":"Mapping the interplay between NK cells and HIV: therapeutic implications","volume":"113","author":"Anderko","year":"2023","journal-title":"J Leukoc Biol"},{"key":"2025030420230820900_vkae028-B7","doi-asserted-by":"crossref","first-page":"879124","DOI":"10.3389\/fimmu.2022.879124","article-title":"Natural killer cells in antibody independent and antibody dependent HIV control","volume":"13","author":"Bernard","year":"2022","journal-title":"Front Immunol"},{"key":"2025030420230820900_vkae028-B8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1021\/acsinfecdis.8b00167","article-title":"Harnessing antibody-dependent cellular cytotoxicity to control HIV-1 infection","volume":"5","author":"Abuharfeil","year":"2019","journal-title":"ACS Infect Dis"},{"key":"2025030420230820900_vkae028-B9","doi-asserted-by":"crossref","first-page":"10844","DOI":"10.1038\/ncomms10844","article-title":"Elimination of HIV-1-infected cells by broadly neutralizing antibodies","volume":"7","author":"Bruel","year":"2016","journal-title":"Nat Commun"},{"key":"2025030420230820900_vkae028-B10","first-page":"373","article-title":"HIV-1-Specific Antibody-Dependent Cellular Cytotoxicity (ADCC)","volume":"17","author":"Cox","year":"1999","journal-title":"Methods Mol Med"},{"key":"2025030420230820900_vkae028-B11","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.molimm.2005.07.010","article-title":"High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G","volume":"43","author":"Preithner","year":"2006","journal-title":"Mol Immunol"},{"key":"2025030420230820900_vkae028-B12","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/eji.1830270816","article-title":"Affinity of the interaction between Fc gamma receptor type III (Fc gammaRIII) and monomeric human IgG subclasses. Role of Fc gammaRIII glycosylation","volume":"27","author":"Galon","year":"1997","journal-title":"Eur J Immunol"},{"key":"2025030420230820900_vkae028-B13","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.4049\/jimmunol.157.4.1576","article-title":"The binding epitopes of human CD16 (Fc gamma RIII) monoclonal antibodies. Implications for ligand binding","volume":"157","author":"Tamm","year":"1996","journal-title":"J Immunol"},{"key":"2025030420230820900_vkae028-B14","first-page":"218","article-title":"Receptors for the Fc fragment of IgG on natural killer cells","volume":"12","author":"Trinchieri","year":"1993","journal-title":"Nat Immun"},{"key":"2025030420230820900_vkae028-B15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3109\/08830188909061983","article-title":"Human Fc receptors for IgG","volume":"5","author":"Unkeless","year":"1989","journal-title":"Int Rev Immunol"},{"key":"2025030420230820900_vkae028-B16","doi-asserted-by":"crossref","first-page":"741","DOI":"10.4049\/jimmunol.1301024","article-title":"ADAM17-mediated shedding of FcgammaRIIIA on human NK cells: identification of the cleavage site and relationship with activation","volume":"192","author":"Lajoie","year":"2014","journal-title":"J Immunol"},{"key":"2025030420230820900_vkae028-B17","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1182\/blood-2012-04-425397","article-title":"NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)","volume":"121","author":"Romee","year":"2013","journal-title":"Blood"},{"key":"2025030420230820900_vkae028-B18","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.bbamcr.2012.11.027","article-title":"ADAM17 cleaves CD16b (FcgammaRIIIb) in human neutrophils","volume":"1833","author":"Wang","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"2025030420230820900_vkae028-B19","doi-asserted-by":"crossref","first-page":"e0121788","DOI":"10.1371\/journal.pone.0121788","article-title":"Identification of an ADAM17 cleavage region in human CD16 (FcgammaRIII) and the engineering of a non-cleavable version of the receptor in NK cells","volume":"10","author":"Jing","year":"2015","journal-title":"PLoS One"},{"key":"2025030420230820900_vkae028-B20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.2019000621","article-title":"Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity","volume":"135","author":"Zhu","year":"2020","journal-title":"Blood"},{"key":"2025030420230820900_vkae028-B21","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/2326-6066.CIR-21-0178","article-title":"Simultaneous engagement of tumor and stroma targeting antibodies by engineered NK-92 cells expressing CD64 controls prostate cancer growth","volume":"9","author":"Hintz","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"2025030420230820900_vkae028-B22","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1080\/14712598.2019.1667974","article-title":"iNK-CD64\/16A cells: a promising approach for ADCC?","volume":"19","author":"Walcheck","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"2025030420230820900_vkae028-B23","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.3389\/fimmu.2018.02873","article-title":"Expression of a recombinant high affinity IgG Fc receptor by engineered NK cells as a docking platform for therapeutic mAbs to target cancer cells","volume":"9","author":"Snyder","year":"2018","journal-title":"Front Immunol"},{"key":"2025030420230820900_vkae028-B24","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.4049\/jimmunol.181.4.2855","article-title":"CD28 costimulation is essential for human T regulatory expansion and function","volume":"181","author":"Golovina","year":"2008","journal-title":"J Immunol"},{"key":"2025030420230820900_vkae028-B25","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/mt.sj.6300134","article-title":"Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules","volume":"15","author":"Suhoski","year":"2007","journal-title":"Mol Ther"},{"key":"2025030420230820900_vkae028-B26","doi-asserted-by":"crossref","first-page":"e007280corr1","DOI":"10.1136\/jitc-2023-007280","article-title":"iPSC-derived natural killer cells expressing the FcgammaR fusion CD64\/16A can be armed with antibodies for multitumor antigen targeting","volume":"11","author":"Snyder","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025030420230820900_vkae028-B27","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.omtm.2021.01.008","article-title":"Systematic improvements in lentiviral transduction of primary human natural killer cells undergoing ex vivo expansion","volume":"20","author":"Allan","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025030420230820900_vkae028-B28","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.3389\/fimmu.2019.02873","article-title":"Efficient and robust NK-cell transduction with baboon envelope pseudotyped lentivector","volume":"10","author":"Colamartino","year":"2019","journal-title":"Front Immunol"},{"key":"2025030420230820900_vkae028-B29","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s12967-020-02526-2","article-title":"Lentiviral delivery of combinatorial CAR\/CRISPRi circuit into human primary T cells is enhanced by TBK1\/IKKvarepsilon complex inhibitor BX795","volume":"18","author":"Li","year":"2020","journal-title":"J Transl Med"},{"key":"2025030420230820900_vkae028-B30","doi-asserted-by":"crossref","DOI":"10.3791\/55063","article-title":"Dextran enhances the lentiviral transduction efficiency of murine and human primary NK cells","author":"Nanbakhsh","year":"2018","journal-title":"J Vis Exp"},{"key":"2025030420230820900_vkae028-B31","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1089\/hum.2012.080","article-title":"Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy","volume":"23","author":"Sutlu","year":"2012","journal-title":"Hum Gene Ther"},{"key":"2025030420230820900_vkae028-B32","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.2174\/138161209789105225","article-title":"NK cell receptors and their interactions with MHC","volume":"15","author":"Biassoni","year":"2009","journal-title":"Curr Pharm Des"},{"key":"2025030420230820900_vkae028-B33","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-065X.1997.tb00946.x","article-title":"Killer cell inhibitory receptors: diversity, specificity, and function","volume":"155","author":"Long","year":"1997","journal-title":"Immunol Rev"},{"key":"2025030420230820900_vkae028-B34","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.immuni.2007.05.006","article-title":"Good news, bad news for missing-self recognition by NK cells: autoimmune control but viral evasion","volume":"26","author":"Vivier","year":"2007","journal-title":"Immunity"},{"key":"2025030420230820900_vkae028-B35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1600-065X.2006.00458.x","article-title":"Licensing of natural killer cells by self-major histocompatibility complex class I","volume":"214","author":"Yokoyama","year":"2006","journal-title":"Immunol Rev"},{"key":"2025030420230820900_vkae028-B36","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/00002030-200303070-00003","article-title":"Inability of natural killer cells to destroy autologous HIV-infected T lymphocytes","volume":"17","author":"Bonaparte","year":"2003","journal-title":"AIDS"},{"key":"2025030420230820900_vkae028-B37","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.4049\/jimmunol.179.4.2097","article-title":"NK cell lysis of HIV-1-infected autologous CD4 primary T cells: requirement for IFN-mediated NK activation by plasmacytoid dendritic cells","volume":"179","author":"Tomescu","year":"2007","journal-title":"J Immunol"},{"key":"2025030420230820900_vkae028-B38","doi-asserted-by":"crossref","first-page":"e1000101","DOI":"10.1371\/journal.ppat.1000101","article-title":"Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals","volume":"4","author":"Fogli","year":"2008","journal-title":"PLoS Pathog"},{"key":"2025030420230820900_vkae028-B39","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1097\/QAD.0000000000000777","article-title":"Lysis of HIV-1-infected autologous CD4+ primary T cells by interferon-alpha-activated NK cells requires NKp46 and NKG2D","volume":"29","author":"Tomescu","year":"2015","journal-title":"AIDS"},{"key":"2025030420230820900_vkae028-B40","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/eji.202149188","article-title":"Identification of the predominant human NK cell effector subset mediating ADCC against HIV-infected targets coated with BNAbs or plasma from PLWH","volume":"51","author":"Tomescu","year":"2021","journal-title":"Eur J Immunol"},{"key":"2025030420230820900_vkae028-B41","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/QAD.0000000000001380","article-title":"IFN-alpha augments natural killer-mediated antibody-dependent cellular cytotoxicity of HIV-1-infected autologous CD4+ T cells regardless of major histocompatibility complex class 1 downregulation","volume":"31","author":"Tomescu","year":"2017","journal-title":"AIDS"},{"key":"2025030420230820900_vkae028-B42","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/s41591-020-1039-5","article-title":"Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo","volume":"26","author":"Maldini","year":"2020","journal-title":"Nat Med"},{"key":"2025030420230820900_vkae028-B43","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00262-016-1803-z","article-title":"CD57 in human natural killer cells and T-lymphocytes","volume":"65","author":"Kared","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"2025030420230820900_vkae028-B44","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1074\/mcp.M112.024596","article-title":"Proteome analysis of distinct developmental stages of human natural killer (NK) cells","volume":"12","author":"Scheiter","year":"2013","journal-title":"Mol Cell Proteomics"},{"key":"2025030420230820900_vkae028-B45","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3389\/fimmu.2013.00422","article-title":"Functional significance of CD57 expression on human NK cells and relevance to disease","volume":"4","author":"Nielsen","year":"2013","journal-title":"Front Immunol"},{"key":"2025030420230820900_vkae028-B46","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2010-04-282301","article-title":"CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset","volume":"116","author":"Lopez-Verg\u00e8s","year":"2010","journal-title":"Blood"},{"key":"2025030420230820900_vkae028-B47","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat Med"},{"key":"2025030420230820900_vkae028-B48","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1182\/blood-2004-02-0696","article-title":"Killing of human immunodeficiency virus-infected primary T-cell blasts by autologous natural killer cells is dependent on the ability of the virus to alter the expression of major histocompatibility complex class I molecules","volume":"104","author":"Bonaparte","year":"2004","journal-title":"Blood"},{"key":"2025030420230820900_vkae028-B49","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"2025030420230820900_vkae028-B50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.intimp.2017.08.016","article-title":"Focus on the therapeutic efficacy of 3BNC117 against HIV-1: In vitro studies, in vivo studies, clinical trials and challenges","volume":"52","author":"Liu","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"2025030420230820900_vkae028-B51","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"2025030420230820900_vkae028-B52","doi-asserted-by":"crossref","first-page":"e0219142","DOI":"10.1371\/journal.pone.0219142","article-title":"Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: a randomized, phase 1 study","volume":"14","author":"Cohen","year":"2019","journal-title":"PLoS One"},{"key":"2025030420230820900_vkae028-B53","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.cell.2014.08.023","article-title":"Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity","volume":"158","author":"Bournazos","year":"2014","journal-title":"Cell"},{"key":"2025030420230820900_vkae028-B54","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1189\/jlb.1008635","article-title":"Retention of viability, cytotoxicity, and response to IL-2, IL-15, or IFN-{alpha} by human NK cells after CD107a degranulation","volume":"85","author":"Tomescu","year":"2009","journal-title":"J Leukoc Biol"},{"key":"2025030420230820900_vkae028-B55","doi-asserted-by":"crossref","first-page":"297ra115","DOI":"10.1126\/scitranslmed.aac5722","article-title":"Human NK cell repertoire diversity reflects immune experience and correlates with viral susceptibility","volume":"7","author":"Strauss-Albee","year":"2015","journal-title":"Sci Transl Med"},{"key":"2025030420230820900_vkae028-B56","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.smim.2017.07.011","article-title":"Natural killer cells unleashed: Checkpoint receptor blockade and BiKE\/TriKE utilization in NK-mediated anti-tumor immunotherapy","volume":"31","author":"Davis","year":"2017","journal-title":"Semin Immunol"},{"key":"2025030420230820900_vkae028-B57","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-4939-3684-7_28","article-title":"Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells","volume":"1441","author":"Felices","year":"2016","journal-title":"Methods Mol Biol"},{"key":"2025030420230820900_vkae028-B58","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1080\/21645515.2016.1198455","article-title":"TriKEs and BiKEs join CARs on the cancer immunotherapy highway","volume":"12","author":"Tay","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2025030420230820900_vkae028-B59","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.omtn.2021.10.009","article-title":"Smart exosomes with lymph node homing and immune-amplifying capacities for enhanced immunotherapy of metastatic breast cancer","volume":"26","author":"Ji","year":"2021","journal-title":"Mol Ther Nucleic Acids"},{"key":"2025030420230820900_vkae028-B60","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.1182\/blood-2011-11-389924","article-title":"Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7","volume":"119","author":"Somanchi","year":"2012","journal-title":"Blood"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/214\/2\/253\/61866060\/vkae028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/214\/2\/253\/61866060\/vkae028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T21:33:34Z","timestamp":1741124014000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/214\/2\/253\/8010950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jimmun\/vkae028","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,2,1]]}}}